56 completed, 12 unknown, 8 recruiting, 7 terminated. 26 Phase 2, 24 Phase 3, 21 Phase 1, 14 Not applicable, 13 Phase 4.
Follow Oral Placebo: new trials by email Literature Review of Oral Placebo trials Research Report on Oral Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| Caffeine for Hypoxic Ischemic Encephalopathy Caffeine citrate oral solution, Oral placebo solution - Hypoxic Ischemic Encephalopathy (HIE) | Phase 3 | Recruiting | NICHD Global Network for Women's and Children's Health | 830 | 2026-04-08 | 2026-06-24 |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder Esketamine, Midazolam, Oral Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Janssen Research & Development, LLC | 258 | 2026-01-08 | 2026-09-25 |
| Age-dependent Effects of Smoked and Oral Delta-9-THC Cannabis, Dronabinol, Smoked Placebo - Pain, Abuse, Drug | Phase 1 | Recruiting | University of California, Los Angeles | 103 | 2025-04-30 | 2026-01-07 |
| A Study of Fosmanogepix in Healthy Adult Chinese Subjects Oral Fosmanogepix, IV Fosmanogepix, IV placebo - Healthy | Phase 1 | Completed | Basilea Pharmaceutica | 54 | 2025-04-14 | 2026-04-06 |
| A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis Oral Brepocitinib, Oral Placebo - Cutaneous Sarcoidosis | Phase 2 / Phase 3 | Recruiting | Priovant Therapeutics, Inc. | 168 | 2025-04-09 | 2026-10-21 |
| The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD Oral CBD oil enriched with terpenes, Oral Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Unknown | Bazelet Nehushtan LtD. | 120 | 2024-08-22 | 2024-08-23 |
| Severe Erythema Multiforme - CORTICO Prednisone 20 Mg, Oral Placebo, Methylprednisolone 120 Mg - Erythema Multiforme | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 96 | 2024-05-01 | 2024-02-20 |
| Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients Tadalafil 5mg, BZ371A, Oral Placebo - Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction | Phase 2 | Recruiting | Biozeus Biopharmaceutical S.A. | 72 | 2023-11-22 | 2024-10-22 |
| Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia Buccal Buprenorphine 300 mcg, Buccal Buprenorphine 600 mcg, Buccal Buprenorphine 900 mcg - Analgesia, Abuse Opioids | Phase 4 | Recruiting | Vanderbilt University Medical Center | 120 | 2023-10-19 | 2026-01-12 |
| SMILES: Study of Montelukast in Sickle Cell Disease Montelukast, Oral Placebo - Anemia, Sickle Cell, Sleep-Disordered Breathing | Phase 2 / Phase 3 | Unknown | Great Ormond Street Hospital for Children NHS Foundation Trust | 200 | 2023-10-16 | 2023-11-01 |
| Oral Sialic Acid Product Beauty Efficacy Test Oral placebo, Oral N-acetylneuraminic acid, OralACAI-PLUS - Health Behavior | Completed | Wuhan CASOV Green Biotech Co., Ltd | 83 | 2023-09-25 | 2026-06-10 | |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study Toripalimab, Lenvatinib mesylate capsules, Placebo IV - Intrahepatic Cholangiocarcinoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 480 | 2023-06-19 | 2025-04-23 |
| The Pharmacodynamics of Cannabinoid-Caffeine Combinations Oral Placebo, Oral THC, Oral CBD - Behavioral Pharmacology of Cannabinoids | Early Phase 1 | Completed | Johns Hopkins University | 20 | 2023-01-20 | 2024-10-08 |
| Enhancing the Natriuretic Peptide System in HFpEF MANP, Sacubitril/Valsartan, Oral Placebo - Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases | Phase 1 / Phase 2 | Enrolling by invitation | Horng Chen | 60 | 2022-11-04 | 2025-10-09 |
| CST1-Guided Oral Glucocorticoids Management for CRSwNP Oral Glucocorticoids, Oral placebo - Chronic Rhinosinusitis With Nasal Polyps, Glucocorticoids | Phase 4 | Unknown | Beijing Tongren Hospital | 90 | 2022-10-17 | 2022-10-28 |
| The Effects of Intranasal and Oral Administration of Oxytocin on Responses to Emotional Scenes Oral Oxytocin, Intranasal Oxytocin, Oral placebo - Healthy | Not applicable | Unknown | University of Electronic Science and Technology of China | 160 | 2022-09-20 | 2022-09-08 |
| Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants Oral Placebo, Oral CBG Cannabis - Behavioral Pharmacology of Cannabis | Phase 1 | Completed | University of Maryland, Baltimore | 12 | 2022-08-09 | 2026-07-27 |
| Oxytocin Effects on Self Versus Other Touch oral lollipop with oxytocin (24IU), oral lollipop with placebo - Healthy | Not applicable | Unknown | University of Electronic Science and Technology of China | 40 | 2022-06-22 | 2023-06-12 |
| Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC Oral Delta-8-THC Cannabis, Oral Delta-9-THC Cannabis, Oral Placebo - Behavioral Pharmacology of Cannabis | Phase 1 | Completed | Johns Hopkins University | 28 | 2022-05-23 | 2026-02-17 |
Showing 20 of 89. Sign in to see all of them.
Pain (6) · Anxiety Disorders (3) · Candidemia (3) · Candidiasis, Invasive (3) · Diabetes Mellitus (3) · Fungemia (3) · Marijuana Abuse (3) · Mycoses (3) · Pathologic Processes (3) · Agnosia (2) · Candidiasis (2) · Cocaine-Related Disorders (2) · Depression (2) · Depressive Disorder, Major (2) · Diabetes Mellitus, Type 1 (2)
University of Electronic Science and Technology of China (6) · Mayo Clinic (3) · Alexza Pharmaceuticals, Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · Cairo University (2) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Janssen Research & Development, LLC (2) · Johns Hopkins University (2) · Midwest Biomedical Research (2) · Milton S. Hershey Medical Center (2) · Novo Nordisk A/S (2) · TG Therapeutics, Inc. (2) · University of Colorado, Denver (2) · Aalborg University Hospital (1) · Amgen (1)
United States (56) · China (12) · Italy (9) · Spain (8) · Canada (7) · Germany (7) · United Kingdom (7) · Australia (5) · France (5) · Hungary (5) · Belgium (4) · Brazil (4) · Bulgaria (4) · Denmark (4) · Israel (4)
Keith M Kendrick, PhD (3) · Keith Kendrick, PhD (2) · Shaimaa Gawdat, PhD (2) · Ahmad Shavakhi, M.D. (1) · Aminah Jatoi (1) · Amy Plint, MSc, MD (1) · Anna Wald, MD, MPH (1) · Anthony DelConte (1) · Bonnie W. Ramsey (1) · Candy Estevez, M.Sc (1) · Cecilia Bergeria, PhD (1) · Daniel Larach, MD, MSTR, MA (1) · Dardo G Tomasi, Ph.D. (1)
PMID 33438477, PMID 36001711, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39512280, PMID 39529079, PMID 41787239, PMID 41940006, PMID 42292352, PMID 16343114, PMID 17073887, PMID 19836169, PMID 20818888, PMID 21893650, PMID 23292233, PMID 23715032, PMID 24111645, PMID 24375070, PMID 24967571, PMID 24977401, PMID 25898052, PMID 25972024, PMID 26044291, PMID 26265463, PMID 26288390, PMID 26445139, PMID 26624824, PMID 28595189, PMID 28715852, PMID 28965100, PMID 29049653, PMID 29369091, PMID 29463461, PMID 30811963, PMID 32082606, PMID 32460879, PMID 32557715, PMID 32838813, PMID 32955088, PMID 33300372, PMID 33732892, PMID 33761207, PMID 34397100, PMID 34406619, PMID 34629091, PMID 34775830, PMID 35119481, PMID 35297025, PMID 35410375
2017 (3), 2004 (1), 2014 (1), 2015 (1), 2018 (1), 2019 (1), K23DA057387 (1), N01CN35157 (1), P30CA060553 (1), R01DA057252 (1), R01MH081837 (1), R01MH122548 (1), U01DA038879 (1), U01HL080310 (1)